摘要
目的 分析非小细胞肺癌免疫治疗患者发生静脉血栓栓塞(VTE)的影响因素.方法 选取62例非小细胞癌(NSCLC)免疫治疗患者,收集患者的一般资料、血脂指标[甘油三酯(TG)、总胆固醇(TC)]、凝血功能指标[凝血酶时间(TT)、凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、D-二聚体(D-D)、血小板].NSCLC免疫治疗患者发生VTE的影响因素采用多因素Logistic回归分析.结果 62例NSCLC患者中,发生VTE 36例,未发生VTE 26例.单因素分析结果显示,病理类型可能不是NSCLC免疫治疗患者VTE发生的影响因素(P﹥0.05);性别、年龄、合并基础疾病、临床分期、吸烟史、饮酒史、O型血情况、体重指数(BMI)、美国东部肿瘤协作组(ECOG)体力状况(PS)评分、TG水平、TC水平、TT、PT、APTT、FIB水平、D-D水平、血小板计数均可能是NSCLC免疫治疗患者发生VTE的影响因素(P﹤0.05).多因素Logistic回归分析结果显示,ECOG PS评分≥2分、TG﹥1.7 mmol/L、TC﹥5.2 mmol/L、D-D≥0.5 mg/L均是NSCLC免疫治疗患者VTE发生的独立危险因素(P﹤0.05).结论 NSCLC免疫治疗患者VTE的发生风险较高,ECOG PS评分≥2分、TG﹥1.7 mmol/L、TC﹥5.2 mmol/L、D-D≥0.5 mg/L均是NSCLC免疫治疗患者发生VTE的独立危险因素.
Abstract
Objective To analyze the influencing factors on venous thromboembolism(VTE)in patients with non-small cell lung cancer(NSCLC)under immunotherapy.Method A total of 62 patients under immunotherapy were select-ed,and their general information,blood lipid indicators[triglyceride(TG),total cholesterol(TC)],and coagulation func-tion indicators[thrombin time(TT),prothrombin time(PT),activated partial thromboplastin time(APTT),fibrinogen(FIB),D-dimer(D-D),and platelet]were collected.The influencing factors of VTE occurrence in NSCLC immunothera-py patients were analyzed by multivariate Logistic regression.Result Among 62 NSCLC patients,36 cases had VTE and 26 cases did not.Univariate analysis showed that pathological type may not be influencing factor for VTE occurrence in NSCLC immunotherapy patients(P>0.05).Gender,age,merge underlying diseases,clinical staging,smoking history,alcohol consumption history,blood type O,body mass index(BMI),Eastern Cooperative Oncology Group(ECOG)per-formance status(PS)score,TG level,TC level,TT,PT,APTT,FIB level,D-D level,and platelet count might be influ-encing factors for the occurrence of VTE in NSCLC immunotherapy patients(P<0.05).Multivariate Logistic regression analysis showed that ECOG PS score≥2 points,TG>1.7 mmol/L,TC>5.2 mmol/L,and D-D≥0.5 mg/L were all inde-pendent risk factors for VTE occurrence in NSCLC immunotherapy patients(P<0.05).Conclusion NSCLC immuno-therapy patients have a higher risk of VTE,with ECOG PS score≥2 points,TG>1.7 mmol/L,TC>5.2 mmol/L,and D-D≥0.5 mg/L being independent risk factors for VTE in NSCLC immunotherapy patients.
NETL
NSTL
维普
万方数据